Managing the expanded use of biologics across therapeutic areas: An example from B-cell targeted therapies

American Journal of Managed Care

Volumn 12, Issue SUPPL. 2, 2006, Pages

  Cohen, Marc ^a   Morrow, Thomas ^b   Penna, Peter ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AD 452; ADALIMUMAB; AG 284; ALEFACEPT; AMG 714; ANTISENSE OLIGONUCLEOTIDE; AT 001; BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOLOGICAL RESPONSE MODIFIER; CETUXIMAB; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DPC 333; EFALIZUMAB; ERLOTINIB; ETANERCEPT; EXENDIN 4; GEMCITABINE; INFLIXIMAB; MLN 1202; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PEPTIDE; PIOGLITAZONE; POLYCLONAL ANTIBODY; PRO 70769; R 1594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RITUXIMAB; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VACCINE; VX 702;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; BIOLOGICAL THERAPY; BIOTECHNOLOGY; BLOOD DISEASE; CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INFECTION; INFLAMMATION; MANAGED CARE; MANAGED CARE ORGANIZATION; MEDICAL DECISION MAKING; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOLOGY; PEANUT ALLERGY; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS;

B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; EDUCATION, CONTINUING; FORMULARIES; HUMANS; MANAGED CARE PROGRAMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645468877     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Nagle P. The biopharmaceutical pipeline and a look at the future of specialty drugs. Presented at: Pharmaceutical Care Management Association Specialty Pharmacy Symposium; June 14, 2005; New York, NY.
2. Silverman E. Biologics' looming price tag has payers retooling pharmacy coverage. Biotechnol Healthcare. 2005;April:35-42.
3. Morrow T. Biologics and targeted therapies: a call for leadership to control costs and manage quality. Available at: www.americanhealthcare.com. Accessed October 10, 2005.
4. Carroll J. Plans struggle for control of specialty pharma costs. Manag Care. 2005;14:41-42,45-48.
5. Dong X, Fetterolf D. Specialty pharmacy: an emerging area of interest for medical management. Dis Manag. 2005;8:73-85.
6. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care. 2003;9(suppl 6):S124-S135.
7. The Zitter Group. The managed care injectables index: spring 2005. 2005;2.
8. Penna P. The "biotech" challenge. Manag Care Interface. 2005;18:31-32.
9. Herskovitz S. Payers' dilemma: looming costs for chronic conditions. Biotechnol Healthcare. 2005;April:29-34.
10. Summary: Peanut Allergy Study. Center Watch Clinical Trial Listing Service. Available at: http://www. centerwatch.com/patient/studies/stu81869. html. Accessed November 1, 2005.
11. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003;15:226-236.
12. Managing generation Rx. Medco Drug Trend Report. Available at: http://www.medco.com/art/pdf/Drug_ Trend_2005.pdf. Accessed January 19, 2006.
13. Tarceva receives approval for pancreatic cancer in the United States. Available at: http://www.roche.com/med-cor-2005. Accessed January 19, 2006.
14. Genentech. Pipeline-Development Status of Avastin. Available at: http://www.gene.com/gene/pipeline/status/oncology/avastin. Accessed January 19, 2006.
15. Enbrel [package insert]. Thousand Oaks, Calif: Immunex Corporation; 2005.
16. Lipsy RJ, Fuller MG, Roski J, Mansukani S. Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. J Manag Care Pharm. 2004;10(suppl 3):S4-S9.
17. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Cohen MD. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm. 2004;10:538-542.
18. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591-2602.
19. White B. Considerations in creating a Medicare Part D formulary. A guide for prescription drug plans to appropriate selection of therapeutic agents. Tumor necrosis factor inhibitors: following best practice. Manag Care. 2004;15(suppl 5):17-23.
20. Kocs D, Fendrik AM. Effects of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care. 2003;9:393-400.
21. Rituxan [package insert]. San Francisco, Calif: Genentech, Inc; 2005.
22. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350:2572-2581.
23. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl. 1996;44:13-22.
24. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000; 39:28-33.
25. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22 (suppl 2):1-12.
26. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996;44:47-51.
27. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum. 2002;46:2553-2563.
28. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-1123.
29. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710-4718.
30. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Presented at: Annual Scientific Meeting of the American College of Rheumatology; October 16-21, 2004; San Antonio, Tex.
31. Van Vollenhoven R, Emery P, Fleischmann RM, et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the Dose-ranging Assessment International Clinical Evaluation of Rituximab in RA (DANCER) study. Presented at: Meeting of the European League Against Rheumatism (EULAR); June 8-11, 2005; Vienna, Austria.
32. Emery P, Filipowicz-Sosnowska A, Szczepanski L, et al. Primary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER trial). Presented at: Meeting of the European League Against Rheumatism (EULAR); June 8-11, 2005; Vienna, Austria.
33. Fleischmann RM, Emery P, Filipowicz-Sosnowska A, et al. Coadministration of glucocorticoids does not influence efficacy of, but reduces infusion reactions to, rituximab in rheumatoid arthritis: results from the DANCER study. Presented at: Meeting of the European League Against Rheumatism (EULAR); June 8-11, 2005; Vienna, Austria.
34. Garber K. First-in-class biologic to enter rheumatoid arthritis fray. Nat Biotechnol. 2005;23:1323-1324.
35. Morrow T. Five steps to managing biologics. Biotechnol Healthcare. 2004;March:20-26.